Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oruka Therapeutics Inc (ORKA)

Oruka Therapeutics Inc (ORKA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run?

Valued at $2.79 billion, Oruka Therapeutics (ORKA) is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. ORKA checks those boxes. Since the Trend Seeker issued a new “buy” on March 13, ORKA stock is up 61.22%.

Fundamentals

See More
  • Market Capitalization, $K 3,002,305
  • Shares Outstanding, K 49,543
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,430 K
  • EBIT $ -122 M
  • EBITDA $ -127 M
  • 60-Month Beta -0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.50

Options Overview Details

View History
  • Implied Volatility 144.14% (+9.41%)
  • Historical Volatility 88.83%
  • IV Percentile 81%
  • IV Rank 49.40%
  • IV High 215.40% on 04/10/25
  • IV Low 74.57% on 03/19/26
  • Expected Move (DTE 9) 4.59 (7.41%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 256
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 1.52
  • Today's Open Interest 1,887
  • Open Int (30-Day) 1,228
  • Expected Range 57.36 to 66.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 4
  • High Estimate $-0.49
  • Low Estimate $-0.52
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.32 +96.81%
on 03/12/26
64.61 -4.60%
on 04/08/26
+28.67 (+86.96%)
since 03/06/26
3-Month
26.46 +133.00%
on 01/09/26
64.61 -4.60%
on 04/08/26
+35.24 (+133.48%)
since 01/08/26
52-Week
5.49 +1,023.79%
on 04/09/25
64.61 -4.60%
on 04/08/26
+54.86 (+809.14%)
since 04/08/25

Most Recent Stories

More News
Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run?

Oruka Therapeutics (ORKA) has strong technical momentum and is trading at a new 5-year high. Shares are up nearly 840% over the past year. ORKA maintains a 100% “Buy” technical opinion from Barchart....

ORKA : 61.13 (+0.87%)
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated...

ORKA : 61.13 (+0.87%)
Oruka Therapeutics to Participate in Multiple Upcoming Conferences

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 61.13 (+0.87%)
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies...

ORKA : 61.13 (+0.87%)
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 61.13 (+0.87%)
Oruka Therapeutics Announces New Board Member and Board Transition

MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 61.13 (+0.87%)
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three...

ORKA : 61.13 (+0.87%)
Oruka Therapeutics to Present at Multiple November Investor Conferences

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 61.13 (+0.87%)
Leerink Partners Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

Leerink Partners analyst David Risinger reiterated a Buy rating on Oruka Therapeutics on October 8. The company’s shares closed last Friday at $24.49.Elevate Your Investing Strategy: Take advantage of...

ORKA : 61.13 (+0.87%)
Oruka Therapeutics Announces $180 Million Private Placement

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a...

ORKA : 61.13 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Oruka Therapeutics Inc. is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka Therapeutics Inc., formerly known as ARCA biopharma Inc., is based in WESTMINSTER, Colo.

See More

Key Turning Points

3rd Resistance Point 68.07
2nd Resistance Point 64.37
1st Resistance Point 62.49
Last Price 61.13
1st Support Level 56.91
2nd Support Level 53.21
3rd Support Level 51.33

See More

52-Week High 64.61
Last Price 61.13
Fibonacci 61.8% 42.02
Fibonacci 50% 35.05
Fibonacci 38.2% 28.07
52-Week Low 5.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.